NOV-001 / Novome Biotech - LARVOL DELTA

NOV-001-CL01: Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects (clinicaltrials.gov) - P1/2 | N=153 | Terminated | Sponsor: Novome Biotechnologies Inc | N=115 ➔ 153 | Active, not recruiting ➔ Terminated; Sponsor decision to discontinue study.

Enrollment change • Trial termination • Nephrology

NOV-001-CL01: Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects (clinicaltrials.gov) - P1/2 | N=115 | Active, not recruiting | Sponsor: Novome Biotechnologies Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Apr 2023

Enrollment closed • Trial completion date • Nephrology

NOV-001-CL01: Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects (clinicaltrials.gov) - P1/2 | N=115 | Recruiting | Sponsor: Novome Biotechnologies Inc | Trial primary completion date: Sep 2022 ➔ Dec 2022

Trial primary completion date • Nephrology

NOV-001-CL01: Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects (clinicaltrials.gov) - P1/2 | N=115 | Recruiting | Sponsor: Novome Biotechnologies Inc | N=83 ➔ 115

Enrollment change • Nephrology

"Other studies pending: #reloxaliase (Allena), #PUSH (#niddk) and Sweetstone: #flozin (empa) vs placebo in UA and Ca SF; #SYNB8802 and #NOV-001 for enteric hyperoxaluria; #lumasiran for CaOx stones" (@weddellite)

Clinical • Nephrology